The following is a description of a study from one of the many researchers that our organization has funded.

Signaling Pathways in Lupus

Julie Zikherman, M.D.
University of California, San Francisco
San Francisco, California
Investigating how distinct alleles of the phosphatase CD45 differentially regulate B cell tolerance and systemic autoimmunity

Systemic lupus erythematosus (lupus) is an autoimmune disease that can result in such devastating outcomes as renal failure and death. Treatment strategies for severe lupus rely heavily on medications that are relatively non-specific and carry a heavy burden of morbid side effects. In order to generate more targeted therapies, a more refined understanding of disease progression is needed.

It has been suspected for decades that B cells must play a critical role in disease. Indeed, human and mouse genetic and biochemical studies suggest that lupus is characterized by B cells with abnormal antigen receptor signaling. (An antigen is any substance that causes the immune system to produce antibodies against it.) Most recently, novel biologic therapies targeting B cells have been approved for lupus patients. Yet the mechanisms by which abnormal signaling through the B cell antigen receptor (BCR) produces systemic autoimmune disease remain ill-defined.

Dr. Zikherman’s study using mice will define the biochemical and cellular mechanisms involved to show how abnormal BCR signaling drives lupus progression in humans. The results may suggest more effective targets for treatment.

You may return to the list of research that we have funded.
Translate »

Connect with ANRF Today!

Stay up -to-date with the latest arthritis news, stories and info.​

Make a Donation

Make a one-time or recurring donation and know that you are making a difference by funding cutting-edge arthritis research.

Skip to content